Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 38,7 M
EBIT 2015 -2,40 M
Net income 2015 -6,79 M
Finance 2015 25,4 M
Yield 2015 -
Sales 2016 65,2 M
EBIT 2016 7,27 M
Net income 2016 -2,98 M
Debt 2016 14,6 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 7,19x
EV / Sales 2016 4,88x
Capitalization 303 M
More Financials
Company
IGI Laboratories, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's... 
Sector
Pharmaceuticals
Calendar
07/23Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
05/12 IGI LABORATORIES : To Present At Bank Of America Merrill Lynch 2015 Health Care ..
05/06 IGI LABORATORIES : To Present At Deutsche Bank 40th Annual Health Care Conferenc..
04/28 IGI LABORATORIES : Announces Second ANDA Submission Of 2015
04/28 IGI LABORATORIES : Announces First Quarter 2015 Results
04/27 IGI LABORATORIES : To Hold Conference Call For 1st Quarter 2015 Results
04/24 IGI LABORATORIES : To Hold Conference Call For 1st Quarter 2015 Results
04/13 IGI LABORATORIES : To Present At 14th Annual Needham Healthcare Conference On Ap..
03/26 IGI LABORATORIES : Announces First ANDA Submission Of 2015
More news
Sector news : Pharmaceuticals - NEC
04:06p ACTAVIS : Confirms Appeals Court Ruling Requiring Continued Distribution of NAME..
01:57p ACTAVIS : US appeals court upholds delay in Alzheimer's drug swap
11:31a JOHNSON & JOHNSON : STELARA® Receives CHMP Positive Opinion For Treatment Of Ado..
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions